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CASE REPORT
Two children exhibiting social withdrawal, school refusal,
and underlying generalized anxiety disorder successfully 
treated using a selective serotonin reuptake inhibitor
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Abstract : Generalized anxiety disorder (GAD) sometimes exists in the background of social withdrawal and 
school refusal. Although clinical evidence suggests that selective serotonin reuptake inhibitors (SSRIs) are an ef-
fective treatment for GAD, they are not officially approved for GAD in Japan. In addition, it has been established 
that the use of SSRIs increases the risk for suicide and activation syndrome among young individuals. As such, 
there is currently little domestic clinical experience in prescribing SSRIs to young patients with GAD. The au-
thors report two cases involving 10-year-old patients with GAD who were treated successfully with escitalopram 
and experienced subsequent improvement in social withdrawal and school refusal. One patient had autistic 
spectrum disorder and exhibited self-harm associated with anxiety symptoms, requiring careful use of SSRIs 
under hospitalization. The other patient was treated at an outpatient clinic without any side effects. In each 
case, improvement of anxiety symptoms with the use of SSRIs facilitated the introduction of psychoeducation 
and psychotherapy. It is important to accurately diagnose GAD, which may exist in the background of patients 
exhibiting social withdrawal and school refusal, and to treat the disorder appropriately. J. Med. Invest. 67 : 355-
357, August, 2020
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INTRODUCTION
 
In the field of child psychiatry, social withdrawal and school 
refusal are often caused by psycho-environmental factors such 
as problems at school or in the home. For such cases, it is nec-
essary to appropriately manage these psycho-environmental 
factors. However, depressive episodes or anxiety disorders some-
times exist in the background of social withdrawal and school re-
fusal, which require treatment. Depressive episodes and anxiety 
disorders of specific severity are usually treated with antidepres-
sants such as selective serotonin reuptake inhibitors (SSRIs) 
(1) ; however, younger individuals are known to be at increased 
risk for suicide and activation syndrome induced by these agents 
(2). In particular, we should be cautious when prescribing SSRIs 
to children and adolescents in the early teenage years who have 
difficulty in verbalizing their subjective experiences, and those 
with intellectual or developmental disabilities who are prone to 
exhibit behavioral problems. However, there is a data that sui-
cide risk has been increased as prescriptions of antidepressants 
have been refrained (3) after the United States Food and Drug 
Administration (FDA) warned about the increased suicidality 
risk associated with the use of antidepressants (4). The authors 
report two cases involving 10-year-old children with generalized 
anxiety disorder (GAD) treated with SSRIs, who experienced 
improvement in social withdrawal and school refusal. The par-
ent’s consent was obtained for the publication for each case. 
CASE 1
A 10-year-old girl visited the authors’ facility with complaints 
of anxiety, poor eating habits, and school refusal. She lived with 
her parents and a younger brother. Her father was being treated 
for depression and her younger brother was diagnosed with 
attention deficit hyperactivity disorder. A short stature of 2.2 
SD was recognized. The patient exhibited normal physical and 
language development after birth ; however, she was obsessed 
with specific belongings, had hyperacusis, exhibited one-sided 
conversation and poor communication skills since childhood. 
When she was 7 years of age, she began to worry about stomach 
pain and vomiting and did not regularly eat her school lunch. At 
8 years of age, she became reluctant to attend school, and the 
amount of food intake further decreased, losing weight from 23 
kg to 21 kg. She received inpatient treatment at a general hos-
pital when she was 9 years of age, and her weight recovered to 
27 kg. Even after being discharged from hospital, she felt highly 
anxious about various activities, such as going out, eating, and 
interacting with classmates. With increasing anxiety, self-harm 
was seen, peeling her fingertips, and chewing in the mouth. For 
this reason, she was referred to the authors’ hospital.
Results of the Wechsler Intelligence Scale for Children- Fourth 
Edition (WISC-Ⅳ) revealed a borderline intelligence level (intel-
lectual quotient [IQ], 78 ; Verbal Comprehension Index [VCI], 
86 ; Perceptual Reasoning Index [PRI], 89 ; Working Memory 
index [WMI], 68 ; and Processing Speed Index [PSI], 81). She 
scored 13 points on the Pervasive Developmental Disorders 
Autism Society Japan Rating Scale (PARS), and was above the 
diagnostic threshold for autistic spectrum disorder (ASD). She 
experienced difficulty with understanding sentence meaning, 
metaphors and irony, and experienced persistent deficits in so-
cial communication and interpersonal interaction. She had also 
exhibited a repetitive mode of behavior, interest, and activity. 
In addition, she experienced excessive worry and anxiety about 
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various daily events and activities, and was easily fatigued, with 
restlessness, stiffness, and nervousness. Based on the above, she 
was diagnosed with ASD and GAD. After unsuccessful outpa-
tient treatment, she was admitted to the authors’ department on 
January 30. She stayed in her room and complained about her 
meals and medical examinations. She harmed herself, chewing 
her mouth, and scratching her arms. 
A structured daily schedule was set and behavioral therapy 
using tokens was initiated. Although she achieved a certain level 
of stability in the ward, she continued to worry and was unable 
to go out or attend school ; consequently, pharmacotherapy was 
initiated. A small amount of aripiprazole (approximately 4 mg) 
had no effect. The authors explained to her parents that the 
SSRIs might be effective for GAD, although the drugs were not 
officially approved for GAD in Japan, and that the use of the 
drugs could increase the risk for suicide attempt and activation 
syndrome among young individuals. After obtaining parental 
consent for using SSRIs, escitalopram was used up to 10 mg. She 
began to go out and attend school for disabled children. However, 
she became emotionally unstable, and resumed self-harm, and 
she cried and abused her mother in the hospital room. The emo-
tional response appeared to be due to environmental changes 
such as attending school. However, because there was also con-
cern about activation syndrome from escitalopram, the dose of 
the drug was reduced to 2.5 mg. Anxiety then recurred, and she 
hesitated to attend school. After carefully increasing the dose of 
the drug to 10 mg again, she did not exhibit self-harm or emo-
tional instability and was able to return to a local school after 
attending a school for disabled children. She was discharged 
in September of the same year and, after several visits to the 
authors’ outpatient clinic, was referred to the previous physician. 
The clinical course of the case is shown in Fig.1.
CASE 2
A 10-year-old girl visited the authors’ hospital with various 
complaints and concerns. She lived with her parents and a 
younger brother. There was no family history of mental illness. 
The patient exhibited no particular problems through nursery 
school and kindergarten, and she enjoyed studying and playing 
with her friends at elementary school. However, when she left a 
good friend at class change one month previously, she could not 
adjust to the new class. Gradually, she became unable to sleep 
because she recalled dreadful words such as “war”, “illness”, 
and / or “death”. She was worried that her mother would not re-
turn from shopping, and frequently checked with her and asked 
for assurance. She frequently complained of physical symptoms, 
such as difficulties with swallowing and breathing, and dis-
comfort in the chest and throat. Although she visited a nearby 
pediatrician, there were no abnormal findings. She became more 
ill and began to refuse to attend school. She visited the authors’ 
hospital for the first time.
Although she was nervous, she understood well and conversed 
accordingly, exhibiting no problems with communication. Re-
sults of the WISC-Ⅳrevealed a normal intelligence level (IQ, 
87 ; VCI, 88 ; PRI, 106 ; WMI 82 ; and PSI, 78). She was diag-
nosed with GAD, and was administered tandospirone at the out-
patient clinic at a dose ranging from 15 to 30 mg. Despite some 
reduction in physical symptoms, she continued to worry and re-
fused to attend school. When she saw news of disasters she could 
not go out. Although she liked pets, she was afraid to touch them 
due to fears of contracting an illness, which further contributed 
to withdrawal from life. Tandospirone was discontinued. The 
authors explained to her parents that the SSRIs might be effec-
tive for GAD, although the drugs were not officially approved for 
GAD in Japan, and that the use of the drugs could increase the 
risk for suicide attempt and activation syndrome among young 
individuals. After obtaining parental consent for using SSRIs, 
escitalopram was started at 2.5 mg and increased to 5 mg. 
Gradually, her symptoms decreased and virtually disappeared. 
Although refusal to attend school was prolonged, she was able to 
start short-term individual classes, and then was able to gradu-
ally return to normal school after 3 months of SSRI treatment. 
The clinical course of the case is shown in Fig.2.
 
DISCUSSION
There is sufficient evidence supporting SSRIs as an effective 
treatment for GAD, as well as major depressive, panic, and social 
anxiety disorders(5). However, unlike other countries, no SSRIs 
have yet been formally approved for GAD in Japan ; therefore, it 
is necessary to explain the off-label use when prescribing them. 
More importantly, the use of SSRIs and other antidepressants 
are known to be associated with higher risks for inducing sui-
cide and activation syndrome in young individuals compared 
with adults(2). Therefore, it should be extremely cautious to use 
Figure 1.　The clinical course of case 1
Figure 2.　The clinical course of case 2
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SSRIs in children with GAD based on consideration of the risks 
as well as off-label prescription.
Nevertheless, GAD in childhood is, by no means, rare(6). The 
authors presented two cases involving children with social with-
drawal and school refusal with underlying GAD. In each case, 
GAD was improved by carefully using escitalopram, and symp-
tomatic improvement led to recovery from social withdrawal and 
school refusal. The first case had ASD and had self-harm ; as 
such, the SSRI was used in an inpatient setting. The emotional 
instability and re-emergence of self-harm that appeared when 
she became able to go out and attend school were believed to be 
due to a psychological reaction due to an environmental change 
but not due to activation syndrome. The second patient was 
treated on an outpatient basis at a low dose of the SSRI and 
experienced no specific side effects. In both cases, improvement 
in anxiety symptoms using an SSRI facilitated the introduction 
of psychoeducation and psychotherapy. These findings suggest 
that it is important to accurately diagnose GAD, which may be 
present in the background of patients with social withdrawal 
and school refusal, and to treat the disorder appropriately.
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